These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. Barnett BS; Parker SE; Weleff J Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734 [TBL] [Abstract][Full Text] [Related]
4. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784 [TBL] [Abstract][Full Text] [Related]
5. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics. Wilkes R; Roberts DM; Liknaitzky P; Brett J Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585 [TBL] [Abstract][Full Text] [Related]
6. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717 [TBL] [Abstract][Full Text] [Related]
8. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview. Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266 [TBL] [Abstract][Full Text] [Related]
9. Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT Exp Clin Psychopharmacol; 2021 Oct; 29(5):539-554. PubMed ID: 34096755 [TBL] [Abstract][Full Text] [Related]
10. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy of psychedelics in psychiatry, a systematic review of the literature]. Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297 [TBL] [Abstract][Full Text] [Related]
12. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Bender D; Hellerstein DJ Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823 [TBL] [Abstract][Full Text] [Related]
13. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322 [TBL] [Abstract][Full Text] [Related]
14. Dosing Psychedelics and MDMA. Liechti ME; Holze F Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392 [TBL] [Abstract][Full Text] [Related]
15. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. Leger RF; Unterwald EM J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567 [TBL] [Abstract][Full Text] [Related]
16. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. Barnett BS; Greer GR J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406 [TBL] [Abstract][Full Text] [Related]
17. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898 [TBL] [Abstract][Full Text] [Related]
18. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555 [TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078 [TBL] [Abstract][Full Text] [Related]
20. Analysis of recreational psychedelic substance use experiences classified by substance. Hase A; Erdmann M; Limbach V; Hasler G Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]